Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 3Terminated 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 6Lymphoma, Extranodal NK-T-Cell 6Carcinoma, Hepatocellular 5Stomach Neoplasms 3Nasopharyngeal Carcinoma 3Locally Advanced Rectal Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Melanoma 2Epstein-Barr Virus Infections 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Objective Response Rate 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, T-Cell 1Lymphoma 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1

Interventions

Cisplatin 32Paclitaxel 29Radiotherapy 21Fluorouracil 20Radiation 12camrelizumab 11Oxaliplatin 11Docetaxel 11Carboplatin 10Capecitabine 9Esophagectomy 8Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 6Leucovorin 6Endoscopic Mucosal Resection 6Drug Therapy 6apatinib 5Neoadjuvant Therapy 5Chemoradiotherapy 5nedaplatin 4S 1 (combination) 4Preoperative Exercise 4Irinotecan 4Endoscopy 4Cetuximab 4Albumin-Bound Paclitaxel 4pembrolizumab 3TP protocol 3Radiotherapy, Adjuvant 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Esophageal Neoplasms × spartalizumab × Clear all
NCT03671265 2019-01-09

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
20 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡